Rockwell Medical (NASDAQ:RMTI) Upgraded to Hold at Zacks Research

Rockwell Medical (NASDAQ:RMTI) was upgraded by investment analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Thursday, Zacks reports.

Several other brokerages have also weighed in on RMTI. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Rockwell Medical in a research report on Friday, September 11th. Wall Street Zen raised Rockwell Medical to a “hold” rating in a research note on Saturday, July 25th. Finally, Weiss Ratings upgraded Rockwell Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, October 8th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $20.00.

Rockwell Medical Trading Down 4.7%

Shares of Rockwell Medical stock traded down $0.35 during mid-day trading on Thursday, hitting $7.03. The stock had a trading volume of 42,451 shares, compared to its average volume of 24,348. The firm has a 50-day moving average of $7.80 and a two-hundred day moving average of $8.07. Rockwell Medical has a 12-month low of $4.89 and a 12-month high of $12.90. The company has a quick ratio of 3.00, a current ratio of 3.25 and a debt-to-equity ratio of 0.21. The firm has a market cap of $28.33 million, a P/E ratio of -4.92 and a beta of 1.75.

Rockwell Medical (NASDAQ:RMTI) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.41). The firm had revenue of $19.12 million for the quarter, compared to analyst estimates of $18.22 million. Rockwell Medical had a negative return on equity of 15.72% and a negative net margin of 7.79%. Sell-side analysts forecast that Rockwell Medical will post -0.90 earnings per share for the current year.

Institutional Investors Weigh In On Rockwell Medical

An institutional investor recently bought a new position in Rockwell Medical stock. Corsair Capital Management L.P. acquired a new stake in Rockwell Medical, Inc. (NASDAQ:RMTI) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 50,000 shares of the company’s stock, valued at approximately $45,000. Corsair Capital Management L.P. owned approximately 0.13% of Rockwell Medical as of its most recent filing with the Securities & Exchange Commission. 23.31% of the stock is currently owned by institutional investors.

Key Stories Impacting Rockwell Medical

These are some of the RMTI stories that stood out recently:

• Positive Sentiment: Third-quarter sales rose 20% year over year to $19.1 million, ahead of estimates; gross profit increased 37% to $3.1 million, and gross margin improved to 16% from 14%. Rockwell Medical reports third-quarter sales
• Positive Sentiment: The proposed acquisition of Vantive’s hemodialysis products and related business could substantially expand Rockwell Medical’s scale. Management expects the combined company to generate $400 million to $450 million in annual revenue and targets closing in mid-2027. Combined revenue outlook and Vantive closing target
• Negative Sentiment: Regulatory approvals for the Vantive transaction could bring costly conditions and reduce expected synergies, creating uncertainty around the deal’s benefits and timeline. Regulatory risks around the Vantive transaction

Rockwell Medical Company Profile

Rockwell Medical, Inc. is a healthcare company that develops, manufactures and distributes products used in the treatment of people with kidney disease, particularly patients receiving hemodialysis. Its offerings include acid and bicarbonate concentrates used to prepare dialysis solutions, as well as related supplies and services for dialysis providers. The company has also developed pharmaceutical products for use in dialysis care. Founded in 1996, Rockwell Medical is based in the United States and serves dialysis providers in the U.S. and select international markets.